Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12591111rdf:typepubmed:Citationlld:pubmed
pubmed-article:12591111lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0031119lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0027756lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0254370lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0033414lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:12591111lifeskim:mentionsumls-concept:C0212602lld:lifeskim
pubmed-article:12591111pubmed:issue1-3lld:pubmed
pubmed-article:12591111pubmed:dateCreated2003-2-19lld:pubmed
pubmed-article:12591111pubmed:abstractTextThe neurotrophic and neuroprotective potential of the alpha-melanocyte-stimulating hormone (alpha-MSH) analog cyclo-[Ac-Nle(4),Asp(5),D-Phe(7),Lys(10)]alpha-MSH-(4-10) amide (melanotan-II), a potent melanocortin receptor agonist, was investigated. The sciatic nerve crush model was used as a paradigm to investigate the neurotrophic properties of melanotan-II. Melanotan-II significantly enhanced the recovery of sensory function following a crush lesion of the sciatic nerve in the rat at a dose of 20 microg kg(-1) per 48 h, s.c., but not at a dose of 2 or 50 microg kg(-1). In addition, we observed that melanotan-II also possesses neuroprotective properties, as it partially protected the nerve from a toxic neuropathy induced by cisplatin. Thus, the present data for the first time demonstrate the effectiveness of the potent alpha-MSH analog melanotan-II in nerve regeneration and neuroprotection.lld:pubmed
pubmed-article:12591111pubmed:languageenglld:pubmed
pubmed-article:12591111pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:citationSubsetIMlld:pubmed
pubmed-article:12591111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12591111pubmed:statusMEDLINElld:pubmed
pubmed-article:12591111pubmed:monthFeblld:pubmed
pubmed-article:12591111pubmed:issn0014-2999lld:pubmed
pubmed-article:12591111pubmed:authorpubmed-author:GispenWillem...lld:pubmed
pubmed-article:12591111pubmed:authorpubmed-author:HamersFrank...lld:pubmed
pubmed-article:12591111pubmed:authorpubmed-author:Ter...lld:pubmed
pubmed-article:12591111pubmed:authorpubmed-author:BrakkeeJan...lld:pubmed
pubmed-article:12591111pubmed:authorpubmed-author:AdanRoger A...lld:pubmed
pubmed-article:12591111pubmed:issnTypePrintlld:pubmed
pubmed-article:12591111pubmed:day21lld:pubmed
pubmed-article:12591111pubmed:volume462lld:pubmed
pubmed-article:12591111pubmed:ownerNLMlld:pubmed
pubmed-article:12591111pubmed:authorsCompleteYlld:pubmed
pubmed-article:12591111pubmed:pagination179-83lld:pubmed
pubmed-article:12591111pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:meshHeadingpubmed-meshheading:12591111...lld:pubmed
pubmed-article:12591111pubmed:year2003lld:pubmed
pubmed-article:12591111pubmed:articleTitleThe potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat.lld:pubmed
pubmed-article:12591111pubmed:affiliationDepartment of Medical Pharmacology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG, Utrecht, The Netherlands.lld:pubmed
pubmed-article:12591111pubmed:publicationTypeJournal Articlelld:pubmed